Pharnext (FR:ALPHA) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Pharnext SCA, a biopharmaceutical company focusing on treatments for neurodegenerative diseases, has defaulted on its convertible bond financial agreement with Global Tech Opportunities 13, which may now terminate the contract. The company has also requested judicial liquidation and cautions that asset sales are unlikely to benefit shareholders due to substantial liabilities and the expected dilutive effect of securities issued for financing.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
